Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) traded up 5.6% during trading on Monday . The company traded as high as $1.14 and last traded at $1.13. 308,303 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 458,218 shares. The stock had previously closed at $1.07.
Tiziana Life Sciences Stock Down 5.6 %
The firm has a 50 day simple moving average of $1.14 and a two-hundred day simple moving average of $0.95.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of TLSA. Zhang Financial LLC boosted its position in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company's stock worth $65,000 after purchasing an additional 23,800 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after acquiring an additional 27,041 shares in the last quarter. Finally, Bison Wealth LLC acquired a new position in Tiziana Life Sciences in the fourth quarter valued at about $30,000.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Stories
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
